| Company Name: | BOC Sciences Gold |
| Tel: | 1-631-504-6093 |
| Email: | sales@bocsci.com |
| Products Intro: |
Product Name:AzithroMycin
CAS:83905-01-5
|
| Company Name: | J & K SCIENTIFIC LTD. |
| Tel: | 400-666-7788 +86-10-82848833 |
| Email: | jkinfo@jkchemical.com;market3@jkchemical.com |
| Products Intro: |
Product Name:AzithroMycin
CAS:83905-01-5
Purity:98% Package:1G,5G |
| Company Name: | Meryer (Shanghai) Chemical Technology Co., Ltd. |
| Tel: | +86-(0)21-61259100(Shanghai) +86-(0)755-86170099(ShenZhen) +86-(0)10-59487313(Beijing) |
| Email: | sh@meryer.com |
| Products Intro: |
Product Name:AzithroMycin
CAS:83905-01-5
Purity:98% Remarks:AAM213708 |
| Company Name: | 3B Pharmachem (Wuhan) International Co.,Ltd. |
| Tel: | 86-21-50328103 * 801、802、803、804 Mobile:18930552037 |
| Email: | 67055399@qq.com |
| Products Intro: |
Product Name:AzithroMycin;13-[(2,6-Dideoxy-3-C-Methyl-3-O-Methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptaMethyl-11-[[3,4,6-trideoxy-3-(diMethylaMino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one
CAS:83905-01-5
Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g |
|
| | Azithromycin Basic information |
| Product Name: | Azithromycin | | Synonyms: | N-METHYL-11-AZA-10-DEOXO-10-DIHYDROERYTHROMYCIN A;11-(4-dimethylamino-3-hydroxy-6-methyl-oxan-2-yl)oxy-2-ethyl-3,4,10-tr;11-(4-DIMETHYLAMINO-3-HYDROXY-6-METHYL-TETRAHYDRO-PYRAN-2-YLOXY)-2-ETHYL-3,4,10-TRIHYDROXY-14-(5-HYDROXY-4-METHOXY-4,6-DIMETHYL-TETRAHYDRO-PYRAN-2-YLOXY)-3,5,6,8,10,12,13-HEPTAMETHYL-1-OXA-6-AZA-CYCLOPENTADECAN-15-ONE;9-DEOXO-9ALPHA-METHYL-9ALPHA-AZA-HOMOERYTHROMYCIN A;9-deoxo-9a-methyl-9a-aza-homoerythromycin a;AZITHROMYCIN;AZITHROMYCINE;1-oxa-6-azacyclopentadecan-15-one,13-((2,6-dideoxy-3-c-methyl-3-o-methyl-alpha | | CAS: | 83905-01-5 | | MF: | C38H72N2O12 | | MW: | 748.98 | | EINECS: | | | Product Categories: | Antibiotics;Antibiotic;Antibiotic Explorer;Intermediates & Fine Chemicals;Pharmaceuticals;API's;NeatsMore...Close...;1694 Pharmaceuticals&Personal Care Products;A - KAntibiotics;Antibacterial;Antibiotics A to;Antibiotics A-FAntibiotics;AntiviralAntibiotics;Chemical Structure Class;Interferes with Protein SynthesisAntibiotics;MacrolidesEPA;Mechanism of Action;Spectrum of Activity;veterinary medicine,soluble powder,preparation;Peptide Synthesis/Antibiotics;Pharmaceutical intermediate | | Mol File: | 83905-01-5.mol |  |
| | Azithromycin Chemical Properties |
| mp | 113-115°C | | storage temp. | Store at -20°C | | Stability: | Stable. Incompatible with strong oxidizing agents. | | CAS DataBase Reference | 83905-01-5(CAS DataBase Reference) | | EPA Substance Registry System | 1-Oxa-6-azacyclopentadecan- 15-one, 13-[(2,6-dideoxy-3-C-methyl- 3-O-methyl-.alpha.-L-ribo- hexopyranosyl)oxy]-2-ethyl- 3,4,10-trihydroxy-3,5,6,8, 10,12,14-heptamethyl-11-[[ 3,4,6-trideoxy-3-(dimethylamino)-. beta.-D-xylo-hexopyranosyl] oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S, 13S,14R)-(83905-01-5) |
| | Azithromycin Usage And Synthesis |
| Chemical Properties | White Crystalline Powder | | Usage | Labelled Azithromycin, a semi-synthetic macrolide antibiotic; related to Erythromycin A. Antibacterial. | | Usage | Azithromycin is a semi-synthetic, ring-expanded erythromycin, produced by a Beckmann rearrangement of erythromycin oxime and reduction to the imine ether, followed by reductive methylation. Azithromycin was the first of the azalides and was designed to improve stability and biological half-life of erythromycin A, as well as improve activity against Gram negative bacteria. Since its discovery in 1980 by Djokic and co-workers, azithromycin has enjoyed considerable therapeutic success. | | Usage | Cephalosporin antibiotic | | Usage | Azithromycin is a semi-synthetic, ring-expanded erythromycin produced by a Beckmann rearrangement of erythromycin oxime and reduction to the imine ether, followed by reductive methylation. Azithromycin was the first of the azalides and was designed to improve the stability and biological half-life of erythromycin A, as well as improve activity against Gram negative bacteria. Since its discovery in 1980 by Djokic and co-workers, azithromycin has enjoyed considerable therapeutic success. | | Biological Activity | Macrolide antibiotic. Inhibits 50S ribosomal subunit formation and elongation at transpeptidation step in gram-positive and gram-negative organisms. Orally active with improved pharmacokinetics over erythromycin in mouse models. |
| | Azithromycin Preparation Products And Raw materials |
|